Medicare GLP-1 Coverage: What $50/Month Means for Everyone

Prices verified May 22, 2026 · Updated for 2026

What the Medicare GLP-1 Bridge actually is

For the first time, Medicare will cover GLP-1 medications specifically for weight loss. The Medicare GLP-1 Bridge is a short-term demonstration program running from July 1, 2026 through December 31, 2027. It operates outside the standard Part D benefit, meaning it doesn't count toward your deductible or donut hole calculations.

Who's eligible

Which medications are covered

• Wegovy (semaglutide) — injection and pill forms
• Zepbound (tirzepatide) — KwikPen injection
• Foundayo (orforglipron) — oral tablet

Notably, compounded GLP-1 medications are not covered. The Bridge covers only FDA-approved brand-name products.

What happened to BALANCE

CMS originally planned a two-step approach: the Bridge for 2026, followed by the BALANCE Model starting January 2027 for Medicare Part D. On April 21, 2026, CMS cancelled the BALANCE Model for Medicare Part D, citing concerns that mandatory lifestyle intervention requirements created unnecessary barriers to care. Instead, the Bridge was extended through December 31, 2027.

The BALANCE Model continues for Medicaid, launching in participating states as early as May 2026. Only 13 states currently cover GLP-1s for obesity under Medicaid (down from 16 in 2025).

The ripple effects

For Medicare beneficiaries

This is transformative. An estimated 7–10 million Medicare beneficiaries may be eligible. At $50/month—versus $349–$1,349/month cash-pay—cost drops by 85–96%. The catch: prior authorization adds friction, and not every Part D plan may participate seamlessly in the transition.

For the compounded market

Medicare-eligible patients currently on compounded GLP-1s ($99–$299/month) will have a strong incentive to switch to brand-name through the Bridge ($50/month). This could reduce compounded provider volume in the 65+ demographic while increasing overall GLP-1 adoption.

For commercial insurance

Medicare coverage creates political pressure on commercial insurers. If the government covers GLP-1s for weight loss at $50/month, employer plans face increasing employee pressure to do the same. Several major insurers (Cigna, UnitedHealthcare) have already expanded GLP-1 coverage in 2026.

For medication supply

The biggest uncertainty: can manufacturers produce enough. Adding millions of Medicare patients to existing demand could strain supply chains, particularly for Zepbound (which experienced shortages in 2024–2025). The inclusion of Foundayo (a different molecule with separate manufacturing) may help distribute demand.

What you should do now (if you're on Medicare)

• Confirm your Part D enrollment: You must be actively enrolled in a Part D plan to participate.
• Talk to your provider: They'll need to submit prior authorization attesting to your BMI and qualifying conditions.
• Don't wait until July 1: Prior authorization can take weeks. Start the process in June.
• Understand the transition risk: The Bridge runs through 2027, but what happens after that is uncertain. Plan for the possibility of reverting to cash-pay if the program isn't extended.

What you should do now (if you're NOT on Medicare)

The Bridge doesn't directly help commercially insured or uninsured patients, but it indirectly benefits everyone by increasing competitive pressure on pricing. If you're currently paying cash for a GLP-1, the compounded market remains your most affordable option, and the providers below offer verified pricing.